Abstract

The goal of this CORE is to provide investigators in this SPORE with high quality patient data, DNA, RNA, serum, and breast tissues from breast cancer patients and normal control patients, and to make these resources available for future translational studies. The activities of the CORE will be conducted in a way that does not compromise patient confidentiality, yet will be as comprehensive as possible in the materials that are provided. The acquisition of human biospecimens and subsequent cellular and molecular analysis of those specimens within the context of patient data are key to many translational studies of cancer. The Mayo Clinic has a strong tradition of biospecimen acquisition and centralized patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo's Tissue Registry and the Mayo Archives. Currently, the Biospecimen and Accessioning (BAP) and the Tissue and Cell Molecular Analysis (TACMA) Shared Resources of the Mayo Clinic Cancer Center provide normal and neoplastic human tissues for cancer research at Mayo, and are resources of expertise, collaborative support, and service for pathology, immunohistochemistry, laser capture microdissection, tissue microarray preparation, and nucleic acid extraction. The Biospecimens and Patient Registry Core of this SPORE will be integrated with the existing Shared Resources in order to provide a coordinated, centralized, dedicated program for procuring, processing, and assessing biospecimens and patient data from breast cancer patients and to provide these specimens for research projects within this SPORE and to other investigators with translational research projects. This CORE will interact closely with the Biostatistics Core of this SPORE to integrate data into a single database and to provide specimens that meet the statistical requirements for translational research projects supported by this SPORE.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-05
Application #
7890428
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$219,410
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Reese, Jordan M; Bruinsma, Elizabeth S; Nelson, Adam W et al. (2018) ER?-mediated induction of cystatins results in suppression of TGF? signaling and inhibition of triple-negative breast cancer metastasis. Proc Natl Acad Sci U S A 115:E9580-E9589
Lilyquist, Jenna; Ruddy, Kathryn J; Vachon, Celine M et al. (2018) Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. Cancer Epidemiol Biomarkers Prev 27:380-394
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Kannan, Nagarajan; Eaves, Connie J (2018) Macrophages stimulate mammary stem cells. Science 360:1401-1402
Guidugli, Lucia; Shimelis, Hermela; Masica, David L et al. (2018) Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. Am J Hum Genet 102:233-248
Kurmi, Kiran; Hitosugi, Sadae; Wiese, Elizabeth K et al. (2018) Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. Cell Rep 22:1365-1373
Goetz, Matthew P; Sangkuhl, Katrin; Guchelaar, Henk-Jan et al. (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther 103:770-777
Baheti, Saurabh; Tang, Xiaojia; O'Brien, Daniel R et al. (2018) HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data. BMC Bioinformatics 19:271
Hart, Steven N; Hoskin, Tanya; Shimelis, Hermela et al. (2018) Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genet Med :
Yang, Yuzhe; Chan, Jie Ying; Temiz, Nuri A et al. (2018) Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. Horm Cancer 9:371-382

Showing the most recent 10 out of 473 publications